NasdaqGM:VCYTBiotechs
Why Veracyte (VCYT) Is Up 18.0% After Raising 2025 Outlook and Highlighting Afirma Progress
Veracyte reported strong third quarter 2025 results, raising full-year revenue guidance to US$506–510 million and highlighting gains in Decipher and Afirma testing as well as positive net income growth.
Recent research publications suggest Veracyte’s Afirma GRID platform could transform pre-surgical thyroid cancer risk assessment, showcasing ongoing clinical innovation and depth of its genomic data capabilities.
With the upgraded revenue outlook underscoring operational momentum, we'll...